Kaplan–Meier survival curves compared conventional lipid-lowering therapy with and without 3 months of PCSK9 antibody administration for the composite of all-cause death, myocardial infarction, stroke, unstable angina, and ischemia-driven revascularization. This evidence concerns the gene PCSK9 and Stroke.